Background: Clinical trials have demonstrated through core and independent studies that anatomical devices are safe and effective with low complication rates. The rotation rate of shaped breast implants in the literature is 0 to 8.2%. Currently there are no studies evaluating the efficacy of in office ultrasound or clinical rotation vs actual rotation rates seen on high-resolution ultrasound (HRUS). Objectives: The purpose of the study is to demonstrate the ease and reliability of HRUS for evaluating the rotation rate of 2 different brands of anatomic implants and to correlate this with the presumed clinical rate, as well as independent evaluators assessments. Methods: A total of 69 patients were followed up at routine intervals and were evaluated for rotation. Any implant rotated past >30° off of midline (outside 5-7 o'clock) was considered to be rotated. To determine if radiographic rotation was clinically evident, 20 composite patient photos were blindly evaluated. Results: A random total of 69 patients underwent bilateral augmentation mammoplasty with form stable anatimic gel implants using 138 implants. Twenty-nine of the 69 (42%) patients and 37 of the 138 (27%) implants were found to be rotated-using HRUS. Eight of the 69 (12%) patients had bilateral rotations. Independent evaluators were able to identify two of 12 (17%) possible rotations, or 2 rotations in 40 (5%) total implants. Conclusions: Anatomic form stable gel implants are actually rotated up to 25 times more frequently than previously thought, but these rotations do not translate into clinically significant sequela. High-resolution ultrasound is a simple alternative for breast implant surveillance and is better accepted by patients than magnetic resonance imaging (MRI). The clinical value of HRUS is also discussed and recommendations for FDA implant labeling changes are provided in this article.
shaped implant rotation through identification of silicone markers placed on these devices. 5 We undertook this investigation to define our experience with an in-office portable hand-held HRUS (Terason 2000+, Terason, Burlington, MA). We designed the study to use the HRUS technology to answer an additional hot topic in breast implant surgery looking at anatomic implant rotation.
Despite the initial excitement for shaped gel breast implants, adoption into clinical practice has remained in the low single digits (3-5%) within the United States. 6 With the release of shaped devices worldwide in 1993 and later approved for use in the United States in 2013 all three of the major United States breast implant manufacturers now have these approved for use. Even though widely available, many surgeons have been hesitant to implement shaped devices into their breast practice despite manufacture core and independent studies both demonstrating them as safe and effective with low complications rates. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Much of the resistance to increase use revolves around the potential risk for implant rotation.
Rotation rates of shaped devices in the literature range from 0 to 8.2% with multiple studies having follow up of greater than 5 years due to patient enrollment in pre-clinical studies. 5, [7] [8] [9] [10] [11] 20, [23] [24] [25] The majority of these studies detected implant rotation clinically from a new asymmetry or deviation from normal breast contours either reported by the patient or detected on clinical exam. Despite low reported rates of rotation, there are no studies to date that have evaluated the rate of clinically undetectable and otherwise benign rotation of shaped devices.
The purpose of this study was to determine actual anatomic implant orientation and rotation rates in the senior author's practice (WPA Jr) using an in-office HRUS technology, while at the same time evaluating in-office HRUS as a viable implant surveillance technology, and finally to confirm if rotations were clinically evident to a group of blinded reviewers.
METHODS
This prospective study included a total random cohort of 69 female patients who had undergone primary bilateral augmentation mammaplasty by a single surgeon from 2002 to 2013. The patients included in the study were those who returned for a requested postoperative visit from August 2012 to February 2013. The principles outlined in the Declaration of Helsinki were followed for the entirety of the study. Informed written consent was obtained from all individuals who elected to participate in the study. As the senior author was a clinical trial investigator for shaped devices, the majority of these cases occurred prior to US release for use in 2013. All patients were taken to the operating room after implant selection preoperatively using tissue based planning, and surgical technique was precise to fit the dimensions of the selected implant. 26 Two different shaped anatomical devices were used in this study; Allergan's 410 gel implant (Allergan Inc., Irvine, CA) and Mentor's Contour Profile Gel (CPG) implant (Mentor Worldwide LLC, Santa Barbara, CA). Sientra's anatomic device was not studied as the device does not have a raised orientation mark on the implant that is echogenic. The brand of implant was selected by the senior author based on the patient, and surgeons agreed final recommendations and availability of the implants from the manufacturer. The study group included 45 patients (90 implants) who underwent bilateral augmentation with CPG implants and 24 patients (48 implants) with 410 implants (Table 1) . Each case was performed using an inframammary incision with placement of the implant into a dual pane pocket as has been previously described. 22 At the time of follow up, patients were evaluated with an office based HRUS for implant integrity and orientation performed by the same investigator (MS) who has 20+ years of clinical ultrasound experience for all subjects. Mentor's CPG implant has a palpable raised ovoid silicone ridge used for intraoperative orientation of the implant (Figure 1 ). Allergan likewise has two round raised silicone projections on the 410 implant located on the anterior and posterior surfaces (Figure 2 ). Both of these silicone projections are easily visualized using HRUS and were used to determine implant orientation. In order to identify which implants were rotated, the breast was divided into 12 equal segments like a face of a clock with the 12 to 6 o'clock position representing the midline division ( Figure  3 ). For the purpose of the study any implant with markers positioned between 5 and 7 o'clock was considered to be in "normal" position, representing a rotational arc of up to 30 o off of midline. Implants rotated past 5 or 7 o'clock were considered to be rotated, with a rotational arc of >30 o off of midline. Implant had never been purposefully placed outside these limits by the operating surgeon. Rotational measurements were taken for each breast. Any abnormalities in the shell of the implant were noted as well.
To determine whether radiographic rotation was also clinically evident 20 composite patient photos were chosen for evaluation ( Figure 4 ). These 20 photos were chosen to represent the 69 patient cohort in terms of implant manufacturer, presence or absence of rotation, bilateral vs unilateral rotation, and patient suspicion for possible rotation. Nine of these patients had known unilateral or bilateral rotations as seen by HRUS. The remaining 11 patients had both implants within normal positions. These 20 composite images were then blindly evaluated for signs of clinical rotation by a group of plastic surgery faculty (attendings at University of Texas Southwestern [UTSW] as well as other national and international aesthetic breast surgeons), plastic surgery residents at UTSW, and a group of non-medical evaluators (friends or family of the residents) using a 28 question online survey (www.surverymonkey.com) asking whether the right, left, neither, or both implants appeared to be rotated. All surveys were complete anonymously and participants were not compensated in any way for their participation. A blank sample copy of the survey is available as Supplementary Material at www.aestheticsurgeryjournal.com.
Due to some respondents' feedback suggesting that adequate information was not available from the original 3 view composite pre-post photos, an additional survey composed of 6 pre-and 6 postoperative views was sent to those plastic surgeons who has used >50 shaped devices.
RESULTS
No significant complications or adverse events such as capsular contracture, infection, infection, or bleeding occurred in any of the patients within this study. Data was calculated using unpaired t tests on Prism 6 (GraphPad Software Inc., La Jolla, CA). The average follow-up time was 5 years postoperatively (range, 1 month-10 years). The average implant volume used across all implants was 279 cc (range, 195-440 cc). The average patient age at time of follow up was 34 years (range, 21-53 years). There were a total of 138 implant placed in 69 patients. Forty-eight (35%) of those placed were Allergan 410 devices and the remaining 90 (65%) were Mentor CPGs.
Using the parameters listed above, 37 of 138 (27%) total implants were found to be rotated using HRUS. Rotation occurred in 29 of 69 (42%) patients with 8 of 69 (12%) patients having bilateral rotations. Of the forty-eight 410 implants placed, 13 (27%) were rotated at the time of follow up. Likewise, of the 90 CPG implants placed, 24 (27%) were discovered to be rotated at the time of follow up. Four of the 24 (17%) patients with 410 implants had bilateral rotations whereas 4 of the 45 (9%) patients with CPG implants had bilateral rotation. Two implant ruptures were discovered using HRUS, one CPG, and one 410 implant.
We next attempted to determine which implant characteristics correlated with implant rotation. Manufacturer, volume, implant base width, height, and projection of normally positioned implants were compared to those rotated implants using an unpaired t test. None of these characteristics reached statistical significance (P > 0.05). At the time of follow up patients were asked whether they noticed any abnormalities or symmetries of their implants. Of the 69 patients, 11 patients thought one or both of their implants was rotated. Nine of these 11 (82%) patients were discovered to actually have one or both implants rotated on HRUS.
The survey was sent out to 64 individuals with a total of 32 completing the online survey (50% response rate). Of the 32 respondents, 14 were plastic surgery physicians, 2 plastic surgery fellows (hand and breast/microsurgery), 9 plastic surgery residents, and 7 non-medical professionals. The residents and fellows were combined into a single cohort for evaluation of survey results. A total of 9 (45%) of the 20 patients in the survey had known implant rotations, 3 of these with bilateral rotations. Of the 40 implants evaluated, there was a total of 12 (30%) implant rotations. Because only 3 pre-and postoperative views (Anteriorposterior (AP), three-quarter view, and lateral) were used in the original survey, an additional survey using 6 views (AP, hands above head, right and left three-quarter and lateral views) was sent only to the practicing plastic surgeons who had used shaped gel devices for >50 cases. Seven plastic surgeons completed the secondary survey.
Respondents were asked to choose whether they believed the right implant, left implant, neither, or both implants were rotated. This allowed for a 1 in 4 or 25% chance of correctly choosing which implant was rotated. For this reason, correctly identifying a rotation was defined as great than 25% of respondents choosing that choice, which is greater than the probability of choosing the correct answer by chance. Participants from both the primary and secondary surveys were able to correctly identify 2 rotations out of the 40 (5%) possible implants. This finding is in agreement with currently published literature (0-8.2%). The majority of the respondents in the plastic surgery physician group had used >50 shaped devices for cosmetic breast cases. The experienced surgeons were no better than residents or patients for that matter in correctly identifying rotated implants. To demonstrate the difficulty in identification, the patient in Figure 4 has a bilateral implant rotation as demonstrated on HRUS.
The use of HRUS as an implant screening tool was also evaluated. The surgeon's practice and patients accepted the in-office technology very well. Patients accepted the simple 5-minute exam and were willing to do follow-up exams. Exams were very easy to perform, and in 2 of the patients in the cohort a suspected implant rupture was identified ( Figure 5 ). One patient was subsequently operated on and rupture confirmed. The second patient went on to have a MRI that also returned the same reading of probable rupture.
DISCUSSION
The single biggest revelation of this study is that in-office HRUS is a clear viable alternative for implant follow up and surveillance. Our data is similar to the Bengtson series with good accuracy for identifying implant abnormalities and rupture. 4 The dynamic nature of the HRUS made it simple to decipher implant folds from concerns of shell discontinuity. The echogenicity of the gel of intact implants was uniformly radiolucent vs the 2 suspected ruptures that had a distinctly different radio-opaque appearance (due to more hydrated gel) making identifying any abnormality quite easy ( Figure 6 ). There were no false positive suspected ruptures in this study. Although the same investigator who had an expert level of clinical ultrasound experience performed all of these exams, the senior author (WPA Jr) has easily trained and learned to perform these exams to identify peri-implant fluid and to evaluate shell integrity.
This skill set is an order of magnitude easier than performing surgery. The notion that HRUS is not viable to perform in the plastic surgery office is misguided. The FDA acknowledged the shortcoming of the current MRI recommendations in 2011, and this was felt to be the single most important finding of the whole 5-year follow-up hearing. 2, 3 Based on this study and others we would submit that:
1. In-office HRUS is now an excellent alternative and perhaps better option for long-term surveillance of breast implants. 4 2. The FDA should recognize HRUS as a viable alternative to MRI for breast implant surveillance. 3. Anyone who claims there needs to be more data is ignoring the current data that answer the question, and the reality is that current compliance with MRI is so low that any alternative that is simple and cost-effective will increase patient compliance. Due to the asymmetric configuration of shaped devices even a small rotation may lead to a visible deformity. Lista et al demonstrated the most common reason for revisional surgery in shaped implants as rotation with a rate of 5.2%. 9 One of the major faults in the majority of studies, including the FDA trials, in evaluating shaped devices is the focus on implant malposition instead of rotation. The number of studies looking specifically at rotation rates in shaped devices is sparse, and this is the first study to evaluate these device rotations using HRUS. The senior author has the largest combined study experience in the United States between the different anatomic implants of over 750 patients and 1500 implants. The perceived clinical rotation rate in those patients was 2%. These were either patients who noticed a change in the shape of their breast that was confirmed at the office or patients seen in follow up who were felt to have a rotation by clinical exam. Despite attempts at identifying predictors for possible implant rotation, none were identified. When evaluating for implant manufacturer, implant volume, height, base width, and projection none of these factors were clinically significant (P > 0.05) for future implant rotation. Some may cite differences in Mentor and Allergan implant texturing as a cause for rotation, 18 yet this did not prove true in our study as both manufacturers had the same implant rotation rate of 27%. The notion that there is more tissue adhesion/ velcro effect with macro-textured devices is a marketing concept based on breast reconstruction and tissue expanders (where these is clearly tissue adhesion); however, this does not translate to the majority of breast augmentation patients (W. Adams Jr. and P. Malucci, unpublished data, 2016). Although there was a difference in the number of CPG (90) vs 410 (48) implants used, this difference was not found to have a significant difference on the results.
The survey results were not able to identify any significant positive predictors for clinical identification of implant rotation. An interesting finding is that 82% of patients who suspected a problem actually had a significant rotation on HRUS. This forewarning should be taken seriously when patients present complaining of asymmetries or abnormalities in their breast contours.
When evaluating the survey, it is interesting to note that the overall clinically detectable rotation rate in our cohort was 5%, which is consistent with the rotation rates commonly sighted in the literature. Sixty-nine percent of survey respondents choose <10% as what they believed to be the clinic rotation rate of shaped devices. It is interesting that most practitioners believe the rotation rate is so low (<10%) as this must be the approximate clinical rotation rate they see in their own surgical patients.
Although the risk for rotation is real, current literature cites rates of <10%. Though this number is small, it is still significant enough to deter many practitioners from using shaped gel implants. This discrepancy leads to the question of why use shaped devices at all if 27% are rotated yet still maintain a natural appearance clinically? Or perhaps we shouldn't be worried about rotation because even when it does occur it is only clinically detectable 5% of the time. Although shaped devices were developed to provide a more natural breast shape while retaining upper pole fullness, their ultimate utility in light of this new data remains uncertain. 27 One possibility for not detecting more rotations is that as the capsule forms around the implant, the device is forced into a rounder shape similar to a round implant. One would suspect that shaped devices with taller heights would have more apparent deformities, but this was not the case in our study. The fact that there are no identifiable variables for implant rotation clinically or by HRUS needs further research to understand completely.
One caveat of this study is our definition of a rotation as >30 o off of midline may have led to a deceptively higher rotation rate. Therefore, an additional analysis was performed to see how many implants were rotated ≥45 o off of midline. Using this parameter, 26% of the implants were still found to be rotated, confirming that despite these rotations, clinical detection is still very difficult. Another critique of the study is that standard photography alone is not adequate for identification of implant rotation. However, even though standard photography is unable to identify clinical rotation, they are in fact occurring in 42% of patients. Finally, some may question whether the ultrasound can accurately predict the static real-time orientation of an implant. It is important to remember that this technology is fully validated to diagnose birth defects and normal development in utero and in the breast it is accepted for detailed ultra-sonographic characterization of masses and cysts which are routinely treated clinically without question.
CONCLUSION
In-office HRUS is a technology able to provided clinicians more detailed information regarding implant status, integrity, and rotation. Actual rotation rates are up to 25 times higher than what was previously thought, but these high rotation rates do not translate to clinically significant sequela/ deformity. There are no implant or patient characteristics that are able to predict implant rotation or make clinical detection easier, although patients' own perception of implant orientation and rotation appears to be far more predictive than surgeons' clinical evaluations.
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